Eli Lilly
Entity.
- Evidence
- 322 documents · 97 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 6 May 2026, last seen 14 Oct 2026
- Measured
- 7% of mentions say something specific about it; the rest only name it
- As of
- 15 Oct 2026
Where this comes from
- Clinical Trials Arena · 2026-10-12 · Lilly reports Phase IIIb data on Taltz and Zepbound combination (opens the source in a new tab)
- STAT News · 2026-10-09 · STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more (opens the source in a new tab)
- Endpoints News · 2026-10-08 · Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle (opens the source in a new tab)
- MarketBeat · 2026-10-08 · HWG Holdings LP Buys 6,647 Shares of Eli Lilly and Company $LLY (opens the source in a new tab)
- MarketBeat · 2026-10-08 · Cantor Fitzgerald Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price (opens the source in a new tab)
- 24/7 Wall St. · 2026-10-07 · Lilly’s Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound (opens the source in a new tab)
- MIT Technology Review · 2026-10-06 · Weight-loss drugs show signs of slowing biological aging, say drugmakers (opens the source in a new tab)
- STAT News · 2026-10-06 · STAT+: Lilly’s Jaypirca approved as first-line CLL therapy (opens the source in a new tab)
- Denkstrom · 2026-10-05 · Lilly vereinbarte im April 2026 Kelonia-Kauf für Krebsgentherapie (opens the source in a new tab)
- Fierce Pharma · 2026-10-03 · With FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL (opens the source in a new tab)